Upstream Bio will present expanded efficacy analyses from its Phase 2 VIBRANT trial evaluating verekitug in patients with chronic rhinosinusitis with nasal polyps during a late-breaking session at the American Academy of Allergy, Asthma & Immunology Annual Meeting in 2026. The presentation will feature new analytical findings that account for the impact of concomitant rescue therapy on treatment outcomes.
Verekitug, a monoclonal antibody that targets the thymic stromal lymphopoietin receptor, represents Upstream Bio's approach to treating immune-mediated inflammatory conditions. The company is advancing the candidate across a pipeline that includes severe asthma and chronic obstructive pulmonary disease, in addition to the chronic rhinosinusitis with nasal polyps indication being evaluated in the VIBRANT trial.
The additional analyses address a key variable in evaluating verekitug's efficacy by examining treatment performance independent of rescue medication utilization patterns, providing a more granular assessment of the therapy's clinical benefit in this patient population. The presentation at AAAAI Congress represents a significant milestone in the clinical development program for the investigational asset.